CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Onco News
Mediexplorer.it

Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation often recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs have been widely used to prevent recurr ...


Prasugrel ( Efient ) is superior to Ticagrelor ( Brilique ) for reducing ischaemic events in patients with acute coronary syndrome and a planned invasive strategy. The results of the ISAR-REACT 5 tr ...


The combination of Ticagrelor ( Brilique ) and Aspirin ( Acetylsalicylic acid ) reduces ischaemic events compared with Aspirin alone in patients with stable coronary artery disease and diabetes. The ...


Implantable cardioverter-defibrillator ( ICD ) use is associated with reduced short- and long-term mortality in patients with heart failure. Patients with heart failure are at increased risk of pot ...


Subcutaneous administration of Inclisiran, a small-interfering RNA ( siRNA ) directed against proprotein convertase subtilisin/kexin type 9 ( PCSK9 ), was associated with substantial and sustained low ...


Edoxaban ( Lixiana ) in combination with a P2Y12 inhibitor is noninferior to standard triple therapy for preventing bleeding in patients with atrial fibrillation after coronary stenting. The results ...


At the European Society of Cardiology Congress 2019, researchers from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris, have presented the results from T ...


A large Cleveland Clinic study has shown that weight-loss surgery performed in patients with type 2 diabetes and obesity is associated with a lower risk of death and major adverse cardiovascular event ...


Low-dose Aspirin ( Acetylsalicylic acid ) does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease. The results of the ASPREE ...


Detailed results from the landmark phase III DAPA-HF trial, presented at the ESC Congress 2019, have shown that Dapagliflozin ( Farxiga ), on top of standard of care, has reduced both the incidence of ...


The results from the global phase III PARAGON-HF study, investigating the safety and efficacy of Sacubitril / Valsartan ( Entresto ) versus the active comparator Valsartan in HFpEF ( heart failure wit ...


Chronic kidney disease is associated with an increased risk of both bleeding and ischemic cardiovascular events. The purpose of this study was to determine the balance of risks and benefits from th ...


Patients with chronic coronary artery disease ( CAD ) or peripheral artery disease ( PAD ) and history of heart failure ( HF ) are at high risk for major adverse cardiovascular events ( MACE ). Re ...


Patients with left-sided heart failure who get implanted devices to improve the pumping of their hearts may be more likely to develop heart failure on the opposite side of their hearts if they are pre ...


Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of Sacubitril - Valsartan ( Entresto ) therapy is safe and eff ...